Sign In  |  Register  |  About Corte Madera  |  Contact Us

Corte Madera, CA
September 01, 2020 10:27am
7-Day Forecast | Traffic

  • Search Hotels in Corte Madera

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Jazz Pharma Plc (NQ: JAZZ )

125.90 -1.65 (-1.29%)
Streaming Delayed Price Updated: 4:00 PM EDT, May 26, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 623,400
Open 127.14
Bid (Size) 125.69 (1)
Ask (Size) 131.92 (1)
Prev. Close 127.55
Today's Range 125.78 - 127.78
52wk Range 125.35 - 163.31
Shares Outstanding 62,311,104
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Jazz Pharmaceuticals Analysis Reveals THC And CBD Therapy Alleviates MS Spasticity
Treatment with the cannabis-based oral spray Nabiximols has been found to significantly relieve spasticity, a common symptom of multiple sclerosis (MS), according to a new analysis of two MS clinical... 
Via Benzinga
World-First Clinical Trial Using Cannabis-Based Drug To Treat Deadly Brain Tumors Recruits First Patients
Can a cannabis-based medicine help treat aggressive brain tumors? Scientists in the UK are getting closer to answering that question. Ongoing lab research is about to become real-world as the project... 
Via Benzinga

Performance

YTD
-19.48%
-19.48%
1 Month
-10.37%
-10.37%
3 Month
-10.91%
-10.91%
6 Month
-18.23%
-18.23%
1 Year
-15.89%
-15.89%

More News

Read More
Where Jazz Pharmaceuticals Stands With Analysts
Via Benzinga
Jazz Pharma Q1 FY23 Revenue Grows 10% YoY, What About Net Income?
Via Benzinga
Recap: Jazz Pharmaceuticals Q1 Earnings
Via Benzinga
Axsome's New Drug Is Scoring a Win. Is the Stock a Buy?
Via The Motley Fool
Why Avadel Pharma Shares Are Gaining Today
Via Benzinga
The Latest Analyst Ratings for Jazz Pharmaceuticals
Via Benzinga
GlycoMimetics: A Breakthrough In Hematopoietic Stem Cell Transplantation
Via Talk Markets
Pressure BioScience's Pressure-Based Tech Is Ready To Spur Innovation And Growth In A Life Sciences Sector In Flux
Via Benzinga
Why Shares of Avadel Soared This Week
Via The Motley Fool
If You Invested $5,000 in Axsome Therapeutics 5 Years Ago, Here's How Much You Would Have Now
Via The Motley Fool
The Top Healthcare Stocks to Buy With $100
Via The Motley Fool
The Global Cannabis Pharmaceuticals Market Size Is Expected To Surpass $125 Billion by 2028
Via FinancialNewsMedia
Topics Cannabis
Exposures COVID-19 Cannabis
2 Top Biotech Stocks to Buy in April
Via The Motley Fool
The 3 Best Growth Stocks to Buy in the Biotech Sector
Via InvestorPlace
Is Big Pharma Coming For Your Cannabis Business?
Via Benzinga
My Top Cannabis Stock to Buy in 2023 and Hold For 10 Years
Via The Motley Fool
Medical Marijuana Milestone In The UK: Celadon Pharmaceuticals Becomes First Company With License To Sell In Britain
Via Benzinga
Silicon Valley Bank Failure Is Just The Tip Of Financial Iceberg, Could Affect Unexpected Industries
Via Benzinga
Zymeworks Offers Hope for More than Just Long-Term Investors
Via MarketBeat
With Access To $20 Million In Financing, 1606 Corp Is Eyeing CBD Business Acquisitions As It Embarks On An Aggressive Growth Path
Via Benzinga
Pharma Mafia Wants To Conquer Cannabis: Can You Patent A Plant? Jazz Is Trying
Via Benzinga
Why Cannabis Is Recession-Resistant & Turning Challenges Into Opportunities, Industry Expert Explains
Via Benzinga
Jazz Q4 2022 Revenue Grows 8% To $972M, Provides Outlook
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Copyright © 2010-2020 CorteMadera.com & California Media Partners, LLC. All rights reserved.